Cutler Group LP Genmab A/S Call Options Transaction History

Cutler Group LP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2021 Jul 19, 2021	SELL	$32.88 - $44.57 $328,800 - $445,700	-10,000 Closed	0 $0
Q1 2021 Apr 26, 2021	BUY	$30.92 - $44.4 $303,016 - $435,120	9,800 Added 4900.0%	10,000 $16,000
Q4 2020 Jan 21, 2021	SELL	$33.66 - $40.76 $50,489 - $61,140	-1,500 Reduced 88.24%	200 $0
Q3 2020 Oct 27, 2020	SELL	$33.07 - $38.68 $36,377 - $42,548	-1,100 Reduced 39.29%	1,700 $17,000
Q2 2020 Jul 22, 2020	BUY	$20.05 - $33.89 $56,140 - $94,892	2,800 New	2,800 $11,000

229

52.1M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $12.9B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.